Nanomaterial-based therapeutic strategies for systemic autoimmune rheumatic diseases: from molecular mechanisms to preclinical translation
- 1Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University
- 2Department of Rheumatology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City)
- 3Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Abstract
Background: Systemic autoimmune rheumatic diseases (SARDs) are chronic, heterogeneous disorders in which loss of immune tolerance, persistent inflammation, and tissue-specific injury can culminate in irreversible organ damage and fibrosis. Although glucocorticoids, conventional immunosuppressants, biologics, and targeted small molecules have transformed care, long-term treatment remains constrained by systemic toxicity, incomplete tissue selectivity, variable response, and limited ability to restore immune homeostasis.
Main body: Nanomedicine provides a modular framework for improving pharmacokinetics, concentrating therapeutics in diseased tissues, enabling controlled release, and co-delivering immunoregulatory cargos. In this Review, we focus on major SARDs—rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and lupus nephritis (LN), systemic sclerosis (SSc), Sjögren’s disease (SjD), and idiopathic inflammatory myopathies (IIM)—while using selected evidence from adjacent immune-mediated diseases only when it provides transferable engineering or mechanistic lessons. We critically distinguish passive accumulation from demonstrated target engagement, cargo-mediated effects from intrinsic nanomaterial bioactivity, and reduction of collagen deposition from direct mechanistic evidence of antifibrotic action. We also emphasize that acidic pH, reactive oxygen species (ROS), and matrix metalloproteinase (MMP) activity are not universal SARD features but disease-, organ-, stage-, and patient-dependent variables that require quantitative validation before being used as release triggers. Recent single-cell studies further show that macrophage states form disease- and tissue-specific continua rather than a binary M1/M2 system, requiring more precise cellular endpoints.
Conclusions: Translation of SARD nanotherapeutics will depend less on adding engineering complexity than on demonstrating disease-relevant biodistribution, target engagement, physiologically validated responsiveness, causal mechanism, repeated-dose safety, scalable manufacturing, and regulatory-quality characterization. A disease-adapted, author-proposed framework of complementary evidence domains may support more transparent assessment of preclinical nanoplatforms, without implying a validated linear pathway to clinical use.
Related
- Self-Assembling Peptide Hydrogels for Mucosal Drug Delivery: Synthesis, Triggering Strategies, and Therapeutic Applications
- Metabolic and Immunometabolic Neuroprotection in Glaucoma: Mitochondrial Dysfunction, Neuroinflammation, and Emerging Therapeutic Strategies
- Flame-Exposed Aluminium Foil as a Low-Cost, Customizable TEM Grid for Nanomaterial Imaging
- Nanomaterial-Enabled Flexible Wearable Sensors for Sports Monitoring and Rehabilitation: Material Architectures, Interface Design, and Signal Reliability
- Nanomaterial-genetics enables near-infrared-driven genetically targeted neuromodulation
BibTeX
@article{guo2026nanomaterialbased,
title = {{Nanomaterial-based therapeutic strategies for systemic autoimmune rheumatic diseases: from molecular mechanisms to preclinical translation}},
author = {Honghao Guo and Wang Xiang and Liuting Zeng and Wei Xiao and Lingyun Sun},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1981246},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1981246/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Nanomaterial-based therapeutic strategies for systemic autoimmune rheumatic diseases: from molecular mechanisms to preclinical translation
AU - Honghao Guo
AU - Wang Xiang
AU - Liuting Zeng
AU - Wei Xiao
AU - Lingyun Sun
PY - 2026
DA - 2026/10/22
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1981246
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1981246/full
AB - Background: Systemic autoimmune rheumatic diseases (SARDs) are chronic, heterogeneous disorders in which loss of immune tolerance, persistent inflammation, and tissue-specific injury can culminate in irreversible organ damage and fibrosis. Although glucocorticoids, conventional immunosuppressants, biologics, and targeted small molecules have transformed care, long-term treatment remains constrained by systemic toxicity, incomplete tissue selectivity, variable response, and limited ability to restore immune homeostasis. Main body: Nanomedicine provides a modular framework for improving pharmacokinetics, concentrating therapeutics in diseased tissues, enabling controlled release, and co-delivering immunoregulatory cargos. In this Review, we focus on major SARDs—rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and lupus nephritis (LN), systemic sclerosis (SSc), Sjögren’s disease (SjD), and idiopathic inflammatory myopathies (IIM)—while using selected evidence from adjacent immune-mediated diseases only when it provides transferable engineering or mechanistic lessons. We critically distinguish passive accumulation from demonstrated target engagement, cargo-mediated effects from intrinsic nanomaterial bioactivity, and reduction of collagen deposition from direct mechanistic evidence of antifibrotic action. We also emphasize that acidic pH, reactive oxygen species (ROS), and matrix metalloproteinase (MMP) activity are not universal SARD features but disease-, organ-, stage-, and patient-dependent variables that require quantitative validation before being used as release triggers. Recent single-cell studies further show that macrophage states form disease- and tissue-specific continua rather than a binary M1/M2 system, requiring more precise cellular endpoints. Conclusions: Translation of SARD nanotherapeutics will depend less on adding engineering complexity than on demonstrating disease-relevant biodistribution, target engagement, physiologically validated responsiveness, causal mechanism, repeated-dose safety, scalable manufacturing, and regulatory-quality characterization. A disease-adapted, author-proposed framework of complementary evidence domains may support more transparent assessment of preclinical nanoplatforms, without implying a validated linear pathway to clinical use.
SN - 1664-3224
ER -